Evotec
David Hensel is an experienced professional in environmental health and safety, currently serving as the Head of EHS for Germany and Austria at Evotec since April 2024. Previously, Hensel held various leadership roles including Head of HSE at medac GmbH and HSE Head at BioNTech SE and Novartis. Hensel's career began at Stryker as Teamleiter EHS & General Service, with earlier positions at Ohly GmbH and BMW Group. Hensel holds a Master of Business Administration in Sustainability Management from Leuphana University of Lüneburg and a Diplom-Wirtschafts-Ingenieur from Ernst-Abbe-Hochschule Jena, complemented by multiple certifications in environmental and safety management.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.